Chemoradiotherapy

Recent Findings on chemoradiotherapy

• A pooled analysis of long-term survivors with thoracic NUT carcinoma examined radiotherapy and curative-intent chemoradiotherapy in relation to clinical outcomes. Among cases treated with curative radiotherapy or CRT, the median radiotherapy-associated progression-free survival (RT-PFS) was 5.3 months, illustrating the substantial heterogeneity of outcomes in this rare thoracic malignancy 42749595Sep.

• In locally advanced rectal cancer, a study investigated radiomics-derived imaging biomarkers for predicting response to neoadjuvant chemoradiotherapy (nCRT). The study focused on pathological complete response (pCR), an outcome associated with an excellent prognosis, and addressed the limited sensitivity of conventional morphological magnetic resonance imaging, reported as 52–71% in the study context 42747720Sep. The work therefore linked CRT response assessment with advanced imaging, validation of predictive biomarkers, and the potential identification of patients who may achieve complete tumor eradication without conventional pathological evidence of residual disease.

• A phase II, single-arm clinical trial evaluated induction FLOT chemotherapy before neoadjuvant CRT for adenocarcinoma of the distal esophagus and proximal stomach. FLOT was investigated as a pre-CRT systemic treatment strategy, with the objective of assessing its effectiveness when added before neoadjuvant chemoradiotherapy 42742872Sep. This sequential approach is intended to expose systemic disease earlier while retaining CRT as a component of local and regional tumor treatment.

• In patients with resected high-risk head and neck squamous cell carcinoma, investigators studied concurrent pembrolizumab and CRT together with tumor and systemic immune correlates of response. Thirty-four patients received pembrolizumab with CRT 42347893Jun. The study therefore examined a combined treatment involving immune checkpoint blockade, chemotherapy, and radiation therapy, with response-related immune features considered alongside standard clinical factors such as surgery, resection status, and disease-free survival.

• A study of cervical cancer investigated whether hyperthermia could sensitize tumors to CRT. Its mechanistic focus was the c-Myc/WSB1/β-catenin axis, including the effects of the combined treatment on this signaling pathway 42703635Sep. The work addressed a potential strategy for modifying tumor biology to increase sensitivity to chemoradiotherapy, rather than treating radiation and chemotherapy as independent modalities.

• The phase III AdvanTIG-301 study evaluated ociperlimab plus tislelizumab in combination with concurrent CRT for treatment-naïve patients with stage III unresectable non-small cell lung cancer. The trial specifically investigated the safety and efficacy of adding two immunotherapeutic agents to concurrent chemoradiotherapy 42648750Aug. This treatment design combines local thoracic radiation and chemotherapy with immune modulation in a disease setting where unresectability makes definitive non-surgical treatment particularly important; outcomes of interest include response, progression-free survival, overall survival, and treatment-related toxicity.

• NRG Oncology/RTOG 0848 examined whether fluoropyrimidine-sensitized radiotherapy could be added to adjuvant chemotherapy after curative-intent resection of adenocarcinoma of the pancreatic head. The study assessed whether this adjuvant CRT strategy improved overall survival compared with adjuvant chemotherapy alone or an associated chemotherapy-based treatment approach 42456089Jul. Its design addresses the role of postoperative local-regional treatment after surgery, where both recurrence risk and the tolerability of additional radiation are clinically relevant.

• In a genetically engineered mouse model of IDH-mutant glioma, researchers investigated whether prior exposure to the mutant IDH inhibitor vorasidenib altered the effectiveness of subsequent chemoradiation. The study specifically addressed whether upfront targeted inhibition influenced later response to combined chemotherapy and radiation 42555757Aug. This preclinical work connects molecularly targeted therapy with subsequent CRT sensitivity and is relevant to treatment sequencing in IDH-mutant glioma, including tumors that may otherwise be managed with radiation, temozolomide, surgery, or combinations of these approaches.

• The ARISTOTLE phase III randomized trial evaluated the addition of irinotecan to standard preoperative CRT for locally advanced rectal cancer. The trial was designed to determine the effect of concomitant irinotecan during chemoradiotherapy 42508427Jul. This approach tests whether intensifying the chemotherapy component of CRT can improve tumor response before surgery, potentially affecting resection outcomes, local control, and subsequent risks of distant metastasis.

• Across these publications, CRT is being studied not only as a fixed combination of chemotherapy and radiation but also as a platform for treatment intensification and personalization. Examples include induction chemotherapy before CRT, addition of irinotecan or fluoropyrimidine-based radiosensitization, integration of pembrolizumab or other immune therapies, hyperthermia-mediated sensitization, and sequencing with vorasidenib. Clinical and translational assessments include MRI-based imaging, radiomics, immune correlates, molecular signaling pathways, response, progression-free survival, disease-free survival, overall survival, and toxicity.